Literature DB >> 19254752

Histological findings on fetal striatal grafts in a Huntington's disease patient early after transplantation.

P Capetian1, R Knoth, J Maciaczyk, G Pantazis, M Ditter, L Bokla, G B Landwehrmeyer, B Volk, G Nikkhah.   

Abstract

Cell transplantation is a promising therapeutic approach that has the potential to replace damaged host striatal neurons and, thereby, slow down or even reverse clinical signs and symptoms during the otherwise fatal course of Huntington's disease (HD). Open-labeled clinical trials with fetal neural transplantation for HD have demonstrated long-term clinical benefits for HD patients. Here we report a postmortem analysis of an individual with HD 6 months after cell transplantation and demonstrate that cells derived from grafted fetal striatal tissue had developed into graft-derived neurons expressing dopamine-receptor related phosphoprotein (32 kDa) (DARPP-32), neuronal nuclear antigen (NeuN), calretinin and somatostatin. However, a fully mature phenotype, considered by the expression of developmental markers, is not reached by engrafted neurons and not all types of interneurons are being replaced at 6 months, which is the earliest time point human fetal tissue being implanted in a human brain became available for histological analysis. Host-derived tyrosine hydroxylase (TH) fibers had already heavily innervated the transplants and formed synaptic contacts with graft-derived DARPP-32 positive striatal neurons. In parallel, the transplants contained a considerable number of immature neuroepithelial cells (doublecortin+, Sox2+, Prox-1+, ss3-tubulin+) that exhibited a pronounced migration into the surrounding host striatal tissue and considerable mitotic activity. Graft-derived astrocytes could also be found. Interestingly, the immunological host response in the grafted area showed localized increase of immunocompetent host cells within perivascular spaces without deleterious effects on engrafted cells under continuous triple immunosuppressive medication. Thus this study provides for a better understanding of the developmental processes of grafted human fetal striatal neurons in HD and, in addition, has implications for stem cell-based transplantation approaches in the CNS.

Entities:  

Mesh:

Year:  2009        PMID: 19254752     DOI: 10.1016/j.neuroscience.2009.02.035

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  21 in total

Review 1.  Experimental surgical therapies for Huntington's disease.

Authors:  Jelle Demeestere; Wim Vandenberghe
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

Review 2.  Current Neurogenic and Neuroprotective Strategies to Prevent and Treat Neurodegenerative and Neuropsychiatric Disorders.

Authors:  I M Carvalho; P B Coelho; P C Costa; C S Marques; R S Oliveira; D C Ferreira
Journal:  Neuromolecular Med       Date:  2015-09-15       Impact factor: 3.843

3.  Survival of neural progenitors allografted into the CNS of immunocompetent recipients is highly dependent on transplantation site.

Authors:  M Janowski; C Engels; M Gorelik; A Lyczek; S Bernard; J W M Bulte; P Walczak
Journal:  Cell Transplant       Date:  2013-01-02       Impact factor: 4.064

Review 4.  To be or not to be accepted: the role of immunogenicity of neural stem cells following transplantation into the brain in animal and human studies.

Authors:  Philipp Capetian; Máté Döbrössy; Christian Winkler; Marco Prinz; Guido Nikkhah
Journal:  Semin Immunopathol       Date:  2011-05-01       Impact factor: 9.623

Review 5.  Cellular therapy and induced neuronal replacement for Huntington's disease.

Authors:  Abdellatif Benraiss; Steven A Goldman
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

6.  Human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges.

Authors:  Camille Nicoleau; Pedro Viegas; Marc Peschanski; Anselme L Perrier
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

7.  Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration.

Authors:  F Cicchetti; S Saporta; R A Hauser; M Parent; M Saint-Pierre; P R Sanberg; X J Li; J R Parker; Y Chu; E J Mufson; J H Kordower; T B Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-20       Impact factor: 11.205

8.  Use of MR cell tracking to evaluate targeting of glial precursor cells to inflammatory tissue by exploiting the very late antigen-4 docking receptor.

Authors:  Michael Gorelik; Inema Orukari; Joanne Wang; Shashikala Galpoththawela; Heechul Kim; Michael Levy; Assaf A Gilad; Amnon Bar-Shir; Douglas A Kerr; Andre Levchenko; Jeff W M Bulte; Piotr Walczak
Journal:  Radiology       Date:  2012-08-24       Impact factor: 11.105

9.  Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease.

Authors:  Gehan El-Akabawy; Ivan Rattray; Saga M Johansson; Richard Gale; Gillian Bates; Michel Modo
Journal:  BMC Neurosci       Date:  2012-08-09       Impact factor: 3.288

10.  Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models.

Authors:  Yuan-Ta Lin; Yijuang Chern; Che-Kun James Shen; Hsin-Lan Wen; Ya-Chin Chang; Hung Li; Tzu-Hao Cheng; Hsiu Mei Hsieh-Li
Journal:  PLoS One       Date:  2011-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.